Systematic overview of aristolochic acids: Nephrotoxicity, carcinogenicity, and underlying mechanisms

Frontiers in Pharmacology

Volumn 10, Issue JUN, 2019, Pages

  Han, Jiayin ^a   Xian, Zhong ^a   Zhang, Yushi ^a   Liu, Jing ^a   Liang, Aihua ^a  

^a INSTITUTE OF CHINESE MATERIA MEDICA   (China)

Author keywords

Aristolochic acid nephropathy; Aristolochic acids; Balkan endemic nephropathy; Carcinogenicity of aristolochic acids; Mechanisms of nephrotoxicity; Upper tract urothelial carcinoma

Indexed keywords

ARISTOLOCHIC ACID; ORGANIC ANION TRANSPORTER;

BIOTRANSFORMATION; CARCINOGENESIS; CARCINOGENICITY; DNA ADDUCT; DNA REPAIR; GENE MUTATION; HUMAN; INTERSTITIAL NEPHRITIS; NEPHROTOXICITY; NONHUMAN; REVIEW; TRANSITIONAL CELL CARCINOMA;

EID: 85069213511     PISSN: None     EISSN: 16639812     Source Type: Journal    
DOI: 10.3389/fphar.2019.00648     Document Type: Review

References (243)

1. Abdullah, R., Diaz, L. N., Wesseling, S., Rietjens, I. M. (2017). Risk assessment of plant food supplements and other herbal products containing aristolochic acids using the margin of exposure (MOE) approach. Food Addit. Contam. Part A Chem. Anal. Control Expo. Risk Assess. 34 (2), 135-144. doi: 10.1080/19440049.2016.1266098
2. Ardalan, M. R., Khodaie, L., Nasri, H., Jouyban, A. (2015). Herbs and hazards: risk of aristolochic acid nephropathy in Iran. Iran J. Kidney Dis. 9 (1), 14-17. doi: http://dx.doi.org/
3. Arlt, V. M., Ferluga, D., Stiborova, M., Pfohl-Leszkowicz, A., Vukelic, M., Ceovic, S., et al. (2002). Is aristolochic acid a risk factor for Balkan endemic nephropathy-associated urothelial cancer? Int. J. Cancer 101 (5), 500-502. doi: 10.1002/ijc.10602
4. Arlt, V. M., Meinl, W., Florian, S., Nagy, E., Barta, F., Thomann, M., et al. (2017). Impact of genetic modulation of SULT1A enzymes on DNA adduct formation by aristolochic acids and 3-nitrobenzanthrone. Arch. Toxicol. 91 (4), 1957-1975. doi: 10.1007/s00204-016-1808-6
5. Arlt, V. M., Stiborova, M., Brocke, J., Simoes, M. L., Lord, G. M., Nortier, J. L., et al. (2007). Aristolochic acid mutagenesis: molecular clues to the aetiology of Balkan endemic nephropathy-associated urothelial cancer. Carcinogenesis 28 (11), 2253-2261. doi: 10.1093/carcin/bgm082
6. Arlt, V. M., Zuo, J., Trenz, K., Roufosse, C. A., Lord, G. M., Nortier, J. L., et al. (2011). Gene expression changes induced by the human carcinogen aristolochic acid I in renal and hepatic tissue of mice. Int. J. Cancer 128 (1), 21-32. doi: 10.1002/ijc.25324
7. Attaluri, S. R., Bonala, R., Yang, I. Y., Lukin, M. A., Wen, Y., Grollman, A. P., et al. (2010). DNA adducts of aristolochic acid II: total synthesis and site-specific mutagenesis studies in mammalian cells. Nucleic Acids Res. 38 (1), 339-352. doi: 10.1093/nar/gkp815
8. Aydin, S., Ambroise, J., Cosyns, J. P., Gala, J. L. (2017). TP53 mutations in p53-negative dysplastic urothelial cells from Belgian AAN patients: new evidence for aristolochic acid-induced molecular pathogenesis and carcinogenesis. Mutat. Res. 818, 17-26. doi: 10.1016/j.mrgentox.2017.03.003
9. Aydin, S., Dekairelle, A. F., Ambroise, J., Durant, J. F., Heusterspreute, M., Guiot, Y., et al. (2014). Unambiguous detection of multiple TP53 gene mutations in AAN-associated urothelial cancer in Belgium using laser capture microdissection. PLoS One 9 (9), e106301. doi: 10.1371/journal.pone.0106301
10. Bakhiya, N., Arlt, V. M., Bahn, A., Burckhardt, G., Phillips, D. H., Glatt, H. (2009). Molecular evidence for an involvement of organic anion transporters (OATs) in aristolochic acid nephropathy. Toxicology 264 (1-2), 74-79. doi: 10.1016/j.tox.2009.07.014
11. Balachandran, P., Wei, F., Lin, R. C., Khan, I. A., Pasco, D. S. (2005). Structure activity relationships of aristolochic acid analogues: toxicity in cultured renal epithelial cells. Kidney Int. 67 (5), 1797-1805. doi: 10.1111/j.1523-1755.2005.00277.x
12. Bamias, G., Boletis, J. (2008). Balkan nephropathy: evolution of our knowledge. Am. J. Kidney Dis. 52 (3), 606-616. doi: 10.1053/j.ajkd.2008.05.024
13. Ban, T. H., Min, J. W., Seo, C., Kim, D. R., Lee, Y. H., Chung, B. H., et al. (2018). Update of aristolochic acid nephropathy in Korea. Korean J. Intern. Med. 33 (5), 961-969. doi: 10.3904/kjim.2016.288
14. Baudoux, T., Husson, C., De Prez, E., Jadot, I., Antoine, M. H., Nortier, J. L., et al. (2018). CD4+ and CD8+ T cells exert regulatory properties during experimental acute aristolochic acid nephropathy. Sci. Rep. 8 (1), 5334. doi: 10.1038/s41598-018-23565-2
15. Baudoux, T. E., Pozdzik, A. A., Arlt, V. M., De Prez, E. G., Antoine, M. H., Quellard, N., et al. (2012). Probenecid prevents acute tubular necrosis in a mouse model of aristolochic acid nephropathy. Kidney Int. 82 (10), 1105-1113. doi: 10.1038/ki.2012.264
16. Bhattacharjee, P., Bera, I., Chakraborty, S., Ghoshal, N., Bhattacharyya, D. (2017). Aristolochic acid and its derivatives as inhibitors of snake venom L-amino acid oxidase. Toxicon 138, 1-17. doi: 10.1016/j.toxicon.2017.08.003
17. Bui-Klimke, T., Wu, F. (2014). Evaluating weight of evidence in the mystery of Balkan endemic nephropathy. Risk Anal. 34 (9), 1688-1705. doi: 10.1111/risa.12239
18. Cachet, X., Langrand, J., Bottai, C., Dufat, H., Locatelli-Jouans, C., Nossin, E., et al. (2016). Detection of aristolochic acids I and II in “Chiniy-tref”, a traditional medicinal preparation containing caterpillars feeding on Aristolochia trilobata L. Toxicon 114, 28-30. doi: 10.1016/j.toxicon.2016.02.013
19. Castells, X., Karanovic, S., Ardin, M., Tomic, K., Xylinas, E., Durand, G., et al. (2015). Low-coverage exome sequencing screen in formalin-fixed paraffin-embedded tumors reveals evidence of exposure to carcinogenic aristolochic acid. Cancer Epidemiol. Biomarkers Prev. 24 (12), 1873-1881. doi: 10.1158/1055-9965.EPI-15-0553
20. Chan, W., Luo, H. B., Zheng, Y., Cheng, Y. K., Cai, Z. (2007). Investigation of the metabolism and reductive activation of carcinogenic aristolochic acids in rats. Drug Metab. Dispos. 35 (6), 866-874. doi: 10.1124/dmd.106.013979
21. Chan, W., Pavlovic, N. M., Li, W., Chan, C. K., Liu, J., Deng, K., et al. (2016). Quantitation of aristolochic acids in corn, wheat grain, and soil samples collected in serbia: identifying a novel exposure pathway in the etiology of Balkan endemic nephropathy. J. Agric. Food Chem. 64 (29), 5928-5934. doi: 10.1021/acs.jafc.6b02203
22. Chang, S. Y., Weber, E. J., Sidorenko, V. S., Chapron, A., Yeung, C. K., Gao, C., et al. (2017). Human liver-kidney model elucidates the mechanisms of aristolochic acid nephrotoxicity. JCI Insight 2 (22). doi: 10.1172/jci.insight.95978
23. Chen, C. H., Dickman, K. G., Huang, C. Y., Moriya, M., Shun, C. T., Tai, H. C., et al. (2013). Aristolochic acid-induced upper tract urothelial carcinoma in Taiwan: clinical characteristics and outcomes. Int. J. Cancer 133 (1), 14-20. doi: 10.1002/ijc.28013
24. Chen, C. H., Dickman, K. G., Moriya, M., Zavadil, J., Sidorenko, V. S., Edwards, K. L., et al. (2012). Aristolochic acid-associated urothelial cancer in Taiwan. Proc. Natl. Acad. Sci. U. S. A. 109 (21), 8241-8246. doi: 10.1073/pnas.1119920109
25. Chen, C. J., Yang, Y. H., Lin, M. H., Lee, C. P., Tsan, Y. T., Lai, M. N., et al. (2018). Herbal medicine containing aristolochic acid and the risk of hepatocellular carcinoma in patients with hepatitis B virus infection. Int. J. Cancer. doi: 10.1002/ijc.31544
26. Chen, L., Xie, B. (2004). Determination of the contents of aristolochic acid in Ganluxiaodu Pills by RP-HPLC. J. Zhejiang Chin. Med. Univ. 28 (2), 73-74. doi: 10.16466/j.issn1005-5509.2004.02.045
27. Chen, J., Li, Y., Meng, S., Guo, M. (2007). Determination of aristolochic acid in Xinmazhike Granules. Lishizhen Med. Mater. Med. Res. 18 (11), 2725-2726. doi: 10.3969/j.issn.1008-0805.2007.11.068
28. Chen, Y. (2003). Determination of the contents of aristolochic acid A in Zhushalian Capsule by HPLC. J. Chongqing Med. Univ. 28 (1), 84-86. doi: 10.13406/j.cnki.cyxb.2003.01.027
29. Chen, Y., Hang, Z., Liu, Y., Liu, Y., Liu, Q., Yi, J. (2009). Analysis of aristolochic acid A in Ershiwuweiluronghao Pills. Chin. J. Pharm. Anal. 29 (9), 1458-1461. doi: 10.16155/j.0254-1793.2009.09.006
30. Colin, P., Koenig, P., Ouzzane, A., Berthon, N., Villers, A., Biserte, J., et al. (2009). Environmental factors involved in carcinogenesis of urothelial cell carcinomas of the upper urinary tract. BJU Int. 104 (10), 1436-1440. doi: 10.1111/j.1464-410X.2009.08838.x
31. Cosyns, J. P., Jadoul, M., Squifflet, J. P., De Plaen, J. F., Ferluga, D., van Ypersele de Strihou, C. (1994a). Chinese herbs nephropathy: a clue to Balkan endemic nephropathy? Kidney Int. 45 (6), 1680-1688. doi: 10.1038/ki.1994.220
32. Cosyns, J. P., Jadoul, M., Squifflet, J. P., Van Cangh, P. J., van Ypersele de Strihou, C. (1994b). Urothelial malignancy in nephropathy due to Chinese herbs. Lancet 344 (8916), 188. doi: 10.1016/S0140-6736(94)92786-3
33. Cosyns, J. P., Jadoul, M., Squifflet, J. P., Wese, F. X., van Ypersele de Strihou, C. (1999). Urothelial lesions in Chinese-herb nephropathy. Am. J. Kidney Dis. 33 (6), 1011-1017. doi: 10.1016/S0272-6386(99)70136-8
34. De Broe, M. E. (2012). Chinese herbs nephropathy and Balkan endemic nephropathy: toward a single entity, aristolochic acid nephropathy. Kidney Int. 81 (6), 513-515. doi: 10.1038/ki.2011.428
35. de Jonge, H., Vanrenterghem, Y. (2008). Aristolochic acid: the common culprit of Chinese herbs nephropathy and Balkan endemic nephropathy. Nephrol. Dial. Transplant. 23 (1), 39-41. doi: 10.1093/ndt/gfm667
36. Debelle, F. D., Vanherweghem, J. L., Nortier, J. L. (2008). Aristolochic acid nephropathy: a worldwide problem. Kidney Int. 74 (2), 158-169. doi: 10.1038/ki.2008.129
37. Decleves, A. E., Jadot, I., Colombaro, V., Martin, B., Voisin, V., Nortier, J., et al. (2016). Protective effect of nitric oxide in aristolochic acid-induced toxic acute kidney injury: an old friend with new assets. Exp. Physiol. 101 (1), 193-206. doi: 10.1113/EP085333
38. Depierreux, M., Van Damme, B., Vanden Houte, K., Vanherweghem, J. L. (1994). Pathologic aspects of a newly described nephropathy related to the prolonged use of Chinese herbs. Am. J. Kidney Dis. 24 (2), 172-180. doi: 10.1016/S0272-6386(12)80178-8
39. Dickman, K. G., Sweet, D. H., Bonala, R., Ray, T., Wu, A. (2011). Physiological and molecular characterization of aristolochic acid transport by the kidney. J. Pharmacol. Exp. Ther. 338 (2), 588-597. doi: 10.1124/jpet.111.180984
40. Ding, H., Shen, J., Fei, W., Qian, Y., Xie, T., Liu, Q. (2018). Determination of aristolochic acid A, B, C, D in aristolochia herbs by UPLC-MS/MS. Chin. J. Ethnomed. Ethnopharmacy 27 (18), 38-43.
41. Dong, H., Suzuki, N., Torres, M. C., Bonala, R. R., Johnson, F., Grollman, A. P., et al. (2006). Quantitative determination of aristolochic acid-derived DNA adducts in rats using 32P-postlabeling/polyacrylamide gel electrophoresis analysis. Drug Metab. Dispos. 34 (7), 1122-1127. doi: 10.1124/dmd.105.008706
42. Dong, S., Shang, M., Wang, X., Zhang, S., Li, C., Cai, S. (2009). Chemical constituents isolated from Saruma henryi. J. Chin. Pharm. Sci. 18 (2), 146-150.
43. Dracinska, H., Barta, F., Levova, K., Hudecova, A., Moserova, M., Schmeiser, H. H., et al. (2016). Induction of cytochromes P450 1A1 and 1A2 suppresses formation of DNA adducts by carcinogenic aristolochic acid I in rats in vivo. Toxicology, 344-346, 7-18. doi: 10.1016/j.tox.2016.01.011
44. Gan, S., Han, T., Liu, H., Shi, X., Wu, C. (2013). Determination of aristolochic acid A in Qingxueneixiao Pills by LC-MS-MS. Chin. J. Exp. Tradit. Med. Formulae 19 (16), 163-167. doi: 10.11653/syfj2013160163
45. Ge, X., Zhang, Y., Cai, X., Wu, C., Wang, H. (2010). Limit test for aristolochic acid A in Xinqin Granules by HPLC. Chin. J. Pharm. 41 (8), 604-606.
46. Gokmen, M. R., Cosyns, J. P., Arlt, V. M., Stiborova, M., Phillips, D. H., Schmeiser, H. H., et al. (2013). The epidemiology, diagnosis, and management of aristolochic acid nephropathy: a narrative review. Ann. Int. Med. 158 (6), 469-477. doi: 10.7326/0003-4819-158-6-201303190-00006
47. Gold, L. S., Slone, T. H. (2003). Aristolochic acid, an herbal carcinogen, sold on the web after FDA alert. N. Engl. J. Med. 349 (16), 1576-1577. doi: 10.1056/NEJM200310163491619
48. Grollman, A. P. (2013). Aristolochic acid nephropathy: harbinger of a global iatrogenic disease. Environ. Mol. Mutagen. 54 (1), 1-7. doi: 10.1002/em.21756
49. Grollman, A. P., Shibutani, S., Moriya, M., Miller, F., Wu, L., Moll, U., et al. (2007). Aristolochic acid and the etiology of endemic (Balkan) nephropathy. Proc. Natl. Acad. Sci. U. S. A. 104 (29), 12129-12134. doi: 10.1073/pnas.0701248104
50. Gruia, A. T., Oprean, C., Ivan, A., Cean, A., Cristea, M., Draghia, L., et al. (2018). Balkan endemic nephropathy and aristolochic acid I: an investigation into the role of soil and soil organic matter contamination, as a potential natural exposure pathway. Environ. Geochem. Health 40 (4), 1437-1448. doi: 10.1007/s10653-017-0065-9
51. Guan, W., Li, X., Xiao, J. (2005). Determination of the contents of aristolochic acid in Asari Radix et Rhizoma and its preparations by reversible high performance liquid chromatography. Chin. Remedies Clinics 5 (4), 283-285. doi: 10.3969/j.issn.1671-2560.2005.04.013
52. Han, N., Lu, J., Bi, K., Du, X., Zhou, Y., Zhou, J. (2008). Assaying of aristolochic acid A in 14 traditional Chinese medicines by RP-HPLC. J. Shenyang Pharm. Univ. 25 (2), 115-118. doi: 10.14066/j.cnki.cn21-1349/r.2008.02.005
53. Hashimoto, K., Higuchi, M., Makino, B., Sakakibara, I., Kubo, M., Komatsu, Y., et al. (1998). Quantitative analysis of aristolochic acids, toxic compounds, contained in some medicinal plants. J. Ethnopharmacol. 64 (1999), 185-189. doi: 10.1016/S0378-8741(98)00123-8
54. Hashimoto, K., Higuchi, M., Fau-Makino, B., Makino, B., Fau-Sakakibara, I., Sakakibara, I, Fau-Kubo, M., Kubo, M, Fau-Komatsu, Y., Komatsu, Y, Fau-Maruno, M., et al. (1999). Quantitative analysis of aristolochic acids, toxic compounds, contained in some medicinal plants. J. Ethnopharmacol. 64 (2), 185-189. doi: 10.1016/S0378-8741(98)00123-8
55. Hashimoto, K., Zaitseva, I. N., Bonala, R., Attaluri, S., Ozga, K., Iden, C. R., et al. (2016). Sulfotransferase-1A1-dependent bioactivation of aristolochic acid I and N-hydroxyaristolactam I in human cells. Carcinogenesis 37 (7), 647-655. doi: 10.1093/carcin/bgw045
56. He, S., Tang, X., Sang, T., Zhao, X., Xie, T. (2013). Content determination of aristolochic acid A in Xiaozhongzhitong Tincture by LC-MS/MS. China Pharmacy 24 (20), 1907-1909. doi: 10.6039/j.issn.1001-0408.2013.20.31
57. Heinrich, M., Chan, J., Wanke, S., Neinhuis, C., Simmonds, M. S. (2009). Local uses of Aristolochia species and content of nephrotoxic aristolochic acid 1 and 2-a global assessment based on bibliographic sources. J. Ethnopharmacol. 125 (1), 108-144. doi: 10.1016/j.jep.2009.05.028
58. Hoang, M. L., Chen, C. H., Chen, P. C., Roberts, N. J., Dickman, K. G., Yun, B. H., et al. (2016). Aristolochic acid in the etiology of renal cell carcinoma. Cancer Epidemiol. Biomarkers Prev. 25 (12), 1600-1608. doi: 10.1158/1055-9965.EPI-16-0219
59. Hoang, M. L., Chen, C. H., Sidorenko, V. S., He, J., Dickman, K. G., Yun, B. H., et al. (2013). Mutational signature of aristolochic acid exposure as revealed by whole-exome sequencing. Sci. Transl. Med. 5 (197), 197ra102. doi: 10.1126/scitranslmed.3006200
60. Hranjec, T., Kovac, A., Kos, J., Mao, W., Chen, J. J., Grollman, A. P., et al. (2005). Endemic nephropathy: the case for chronic poisoning by aristolochia. Croat Med. J. 46 (1), 116-125. doi: 10.1503/cmaj.1040752
61. Hsieh, S. C., Lin, I. H., Tseng, W. L., Lee, C. H., Wang, J. D. (2008). Prescription profile of potentially aristolochic acid containing Chinese herbal products: an analysis of National Health Insurance data in Taiwan between 1997 and 2003. Chin. Med. 3, 13. doi: 10.1186/1749-8546-3-13
62. Hu, S. L., Zhang, H. Q., Chan, K., Mei, Q. X. (2004). Studies on the toxicity of Aristolochia manshuriensis (Guanmuton). Toxicology 198 (1-3), 195-201. doi: 10.1016/j.tox.2004.01.026
63. Huang, K., Zhu, X. (2015). Determination of aristolochic acid I in Liujingtoutong Tablet by SPE-HPLC. Tianjin Pharmacy 27 (5), 9-11. doi: 10.3969/j.issn.1006-5687.2015.05.003
64. Huang, Q., Zheng, W., Chi, Z., Lin, G. (2009). Limit detection of aristolochic acid A in Jiangusujin Tablet by HPLC. Strait Pharm. J. 21 (11), 74-75. doi: 10.3969/j.issn.1006-3765.2009.11.033
65. IARC (2002). Some traditional herbal medicines, some mycotoxins, naphthalene and styrene. IARC Monogr. Eval. Carcinog. Risks Hum. 82, 1-556.
66. IARC (2012). Pharmaceuticals. IARC Monogr. Eval. Carcinog. Risks Hum. 100 (Pt A), 1-401.
67. Ioset, J. R., Raoelison, G. E., Hostettmann, K. (2003). Detection of aristolochic acid in Chinese phytomedicines and dietary supplements used as slimming regimens. Food Chem. Toxicol. 41 (1), 29-36. doi: 10.1016/S0278-6915(02)00219-3
68. Ivic, M. (1969). Etiology of endemic nephropathy. Lijec. Vjesn. 91 (12), 1273-1281.
69. Jadot, I., Decleves, A. E., Nortier, J., Caron, N. (2017). An Integrated view of aristolochic acid nephropathy: update of the literature. Int. J. Mol. Sci. 18 (2). doi: 10.3390/ijms18020297
70. Jankovic-Velickovic, L., Stojnev, S., Ristic-Petrovic, A., Dolicanin, Z., Hattori, T., Mukaisho, K., et al. (2011). Pro- and antiapoptotic markers in upper tract urothelial carcinoma associated with Balkan endemic nephropathy. Sci. World J. 11, 1699-1711. doi: 10.1100/2011/752790
71. Jankovic-Velickovic, L., Ristic-Petrovic, A., Stojnev, S., Dolicanin, Z., Hattori, T., Sugihara, H., et al. (2012). Angiogenesis in upper tract urothelial carcinoma associated with Balkan endemic nephropathy. Int. J. Clin. Exp. Pathol. 5 (7), 674-683. doi: 10.5114/fn.2012.30530
72. Jelakovic, B., Castells, X., Tomic, K., Ardin, M., Karanovic, S., Zavadil, J. (2015a). Renal cell carcinomas of chronic kidney disease patients harbor the mutational signature of carcinogenic aristolochic acid. Int. J. Cancer 136 (12), 2967-2972. doi: 10.1002/ijc.29338
73. Jelakovic, B., Karanovic, S., Vukovic-Lela, I., Miller, F., Edwards, K. L., Nikolic, J., et al. (2012). Aristolactam-DNA adducts in the renal cortex: biomarker of environmental exposure to aristolochic acid. Kidney Int. 81 (6), 559-567. doi: 10.1038/ki.2011.371
74. Jelakovic, B., Nikolic, J., Radovanovic, Z., Nortier, J., Cosyns, J. P., Grollman, A. P., et al. (2014). Consensus statement on screening, diagnosis, classification and treatment of endemic (Balkan) nephropathy. Nephrol. Dial. Transplant. 29 (11), 2020-2027. doi: 10.1093/ndt/gft384
75. Jelakovic, B., Vukovic Lela, I., Karanovic, S., Dika, Z., Kos, J., Dickman, K., et al. (2015b). Chronic dietary exposure to aristolochic acid and kidney function in native farmers from a Croatian endemic area and Bosnian immigrants. Clin. J. Am. Soc. Nephrol. 10 (2), 215-223. doi: 10.2215/CJN.03190314
76. Jia, W., Zhao, A., Gao, W., Chen, M., Xiao, P. (2005). New perspectives on the Chinese herbal nephropathy. Phytother. Res. 19 (11), 1001-1002. doi: 10.1002/ptr.1676
77. Jiang, Y., Hu, L., Hao, F. (2007). Determination of the contents of cinnamic acid and aristolochic acid A in two Guanxinsuhe Pills by RP-HPLC. Chin. Traditional Patent Med. 29 (4), 599-601. doi: 10.3969/j.issn.1001-1528.2007.04.048
78. Jin, K., Su, K. K., Li, T., Zhu, X. Q., Wang, Q., Ge, R. S., et al. (2016). Hepatic premalignant alterations triggered by human nephrotoxin aristolochic acid I in canines. Cancer Prev. Res. (Phila) 9 (4), 324-334. doi: 10.1158/1940-6207.CAPR-15-0339
79. Jou, J. H., Li, C. Y., Schelonka, E. P., Lin, C. H., Wu, T. S. (2004). Analysis of the analogues of aristolochic acid and aristolactam in the plant of Aristolochia genus by HPLC. J. Food Drug Anal. 12 (1), 40-45. doi: 10.1016/j.jcs.2003.11.005
80. Jou, J. H., Chen, S., Wu, T. S. (2003). Facile reversed-phase HPLC resolution and quantitative determination of aristolochic acid and aristolactam analogues in traditional Chinese medicine. J. Liq. Chromatogr. Relat. Technol. 26 (18), 3057-3068. doi: 10.1081/JLC-120025422
81. Kabanda, A., Jadoul, M., Lauwerys, R., Bernard, A., van Ypersele de Strihou, C. (1995). Low molecular weight proteinuria in Chinese herbs nephropathy. Kidney Int. 48 (5), 1571-1576. doi: 10.1038/ki.1995.449
82. Kang, D., Li, T. (2008). Determination the content of aristolochic acid A in Hanshibi Granules by HPLC. China Med. Her. 5 (33), 17-18. doi: 10.3969/j.issn.1673-7210.2008.33.011
83. Kong, D., Gao, H., Li, X., Lu, J., Dan, Y. (2015). Rapid determination of eight aristolochic acid analogues in five Aristolochiaceae plants by ultra-high performance liquid chromatography quadrupole/time-of-flight mass spectrometry. J. Chin. Pharm. Sci. 24 (6), 364-375. doi: 10.5246/jcps.2015.06.047
84. Krell, D., Stebbing, J. (2013). Aristolochia: the malignant truth. Lancet Oncol. 14 (1), 25-26. doi: 10.1016/S1470-2045(12)70596-X
85. Kuo, C. H., Lee, C. W., Lin, S. C., Tsai, I. L., Lee, S. S., Tseng, Y. J., et al. (2010). Rapid determination of aristolochic acids I and II in herbal products and biological samples by ultra-high-pressure liquid chromatography-tandem mass spectrometry. Talanta 80 (5), 1672-1680. doi: 10.1016/j.talanta.2009.10.003
86. Kuo, P. C., Li, Y. C., Wu, T. S. (2012). Chemical constituents and pharmacology of the Aristolochia (madou ling) species. J. Tradit. Complement Med. 2 (4), 249-266. doi: 10.1016/S2225-4110(16)30111-0
87. Kwak, D. H., Lee, S. (2016). Aristolochic acid I causes testis toxicity by inhibiting Akt and ERK1/2 phosphorylation. Chem. Res. Toxicol. 29 (1), 117-124. doi: 10.1021/acs.chemrestox.5b00467
88. Kwak, D. H., Park, J. H., Lee, H. S., Moon, J. S., Lee, S. (2014). Aristolochic acid I induces ovarian toxicity by inhibition of Akt phosphorylation. Chem. Res. Toxicol. 27 (12), 2128-2135. doi: 10.1021/tx5003854
89. Lemy, A., Wissing, K. M., Rorive, S., Zlotta, A., Roumeguere, T., Muniz Martinez, M. C., et al. (2008). Late onset of bladder urothelial carcinoma after kidney transplantation for end-stage aristolochic acid nephropathy: a case series with 15-year follow-up. Am. J. Kidney Dis. 51 (3), 471-477. doi: 10.1053/j.ajkd.2007.11.015
90. Letouze, E., Shinde, J., Renault, V., Couchy, G., Blanc, J. F., Tubacher, E., et al. (2017). Mutational signatures reveal the dynamic interplay of risk factors and cellular processes during liver tumorigenesis. Nat. Commun. 8 (1), 1315. doi: 10.1038/s41467-017-01358-x
91. Leung, E. M., Chan, W. (2015). Comparison of DNA and RNA adduct formation: significantly higher levels of RNA than DNA modifications in the internal organs of aristolochic acid-dosed rats. Chem. Res. Toxicol. 28 (2), 248-255. doi: 10.1021/tx500423m
92. Li, G., Chen, S., Wu, L., Chen, J., Zhang, J., Li, X., et al. (2017). Determination of aristolochic acid I in traditional Chinese medicine by UPLC-QQQ-MS. Chin. J. Exp. Tradit. Med. Formulae 23 (13), 61-65. doi: 10.13422/j.cnki.syfjx.2017130061
93. Li, L., Gao, H., Wang, Z., Wang, W. (2006). Determination of aristolochic acid A in Guanxinsuhe Preparations by RP-HPLC. China J. Chin. Mater. Med. 31 (2), 122-124. doi: 10.3321/j.issn:10015302.2006.02.009
94. Li, Q., Liu, Y., Chang, Y., Wang, L., Jia, R., Zhao, Y. (2009). Qingnaozhitong Capsule of aristolochic acid A limited determination. Spec. Wild Econ. Anim. Plant Res. 31 (4), 61-64. doi: 10.3969/j.issn.1001-4721.2009.04.021
95. Li, W., Han, J., Gao, J., Liu, C. (2007). Determination of aristolochic acid A in Rhizoma Asari and Yangxueqingnao Granules using liquid chromatography tandem mass spectrometry. Chin. J. Anal. Chem. 35 (12), 1798-1800. doi: 10.3321/j.issn:0253-3820.2007.12.025
96. Li, W., Hu, Q., Chan, W. (2016). Uptake and accumulation of nephrotoxic and carcinogenic aristolochic acids in food crops grown in Aristolochia Clematitis-contaminated soil and water. J. Agric. Food Chem. 64 (1), 107-112. doi: 10.1021/acs.jafc.5b05089
97. Li, Y. L., Tian, M., Yu, J., Shang, M. Y., Cai, S. Q. (2010). Studies on morphology and aristolochic acid analogue constituents of Asarum campaniflorum and a comparison with two official species of Asari radix et rhizoma. J. Nat. Med. 64 (4), 442-451. doi: 10.1007/s11418-010-0433-6
98. Li, Z., Qin, T., Wang, K., Hackenberg, M., Yan, J., Gao, Y., et al. (2015). Integrated microRNA, mRNA, and protein expression profiling reveals microRNA regulatory networks in rat kidney treated with a carcinogenic dose of aristolochic acid. BMC Genomics 16, 365. doi: 10.1186/s12864-015-1516-2
99. Liang, A., Gao, Y., Zhang, B. (2017). Safety problems and measures of traditional Chinese medicine containing aristolochic acid. China Food Drug Admin. Mag. 11, 17-20.
100. Lin, D. C., Mayakonda, A., Dinh, H. Q., Huang, P., Lin, L., Liu, X., et al. (2017). Genomic and epigenomic heterogeneity of hepatocellular carcinoma. Cancer Res. 77 (9), 2255-2265. doi: 10.1158/0008-5472.CAN-16-2822
101. Lin, W., Chen, X., Liu, K. (2014). Determination of aristolochic acid A in Tiaogu Tablets. Asia-Pac. Tradit. Mediine. 10 (10), 37-38. doi: 10.1111/ajco.12307
102. Liu, C., Chen, Y., Zhao, X., Gong, L., Wang, L. (2003). Determination of aristolochic acid A in Aristolochia mollissima Hance by RP-HPLC. Chin. Traditional Herbal Drugs 34 (12), 87-89. doi: 10.7501/j.issn.0253-2670.2003.12.2003012619
103. Liu, F., Li, Z., Nie, L., Axia, A., Yuan, R., Wang, J. (2015). Determination of aristolochic acids A and heavy metals in Tibetan medicine-Ershiwuweishanhu Pills. J. Tibet Univ. 30 (2), 65-70. doi: 10.16249/j.cnki.54-1034/c.2015.02.011
104. Liu, L., Cao, S., Ji, Y., Zhang, X., Huang, T. (2005). Qualitative and quantitative analysis of aristolochic acids in Chinese materia medica and traditional Chinese patent medicines. Chin. Traditional Patent Med. 27 (8), 938-941. doi: 10.3969/j.issn.1001-1528.2005.08.025
105. Liu, Y., Han, S., Feng, Q., Wang, J. (2011). Determination of aristolochic acids A and B in Chinese herbals and traditional Chinese patent medicines using ultra high performance liquid chromatography-triple quadrupole mass spectrometry. Chin. J. Chromatogr. 29 (11), 1076-1081. doi: 10.3724/SP.J.1123.2011.01076
106. Lord, G. M., Cook, T., Arlt, V. M., Schmeiser, H. H., Williams, G., Pusey, C. D. (2001). Urothelial malignant disease and Chinese herbal nephropathy. Lancet 358 (9292), 1515-1516. doi: 10.1016/S0140-6736(01)06576-X
107. Lord, G. M., Hollstein, M., Arlt, V. M., Roufosse, C., Pusey, C. D., Cook, T., et al. (2004). DNA adducts and p53 mutations in a patient with aristolochic acid-associated nephropathy. Am. J. Kidney Dis. 43 (4), e11-17. doi: 10.1053/j.ajkd.2003.11.024
108. Lord, G. M., Tagore, R., Cook, T., Gower, P., Pusey, C. D. (1999). Nephropathy caused by Chinese herbs in the UK. Lancet 354 (9177), 481-482. doi: 10.1016/S0140-6736(99)03380-2
109. Lukin, M., Zaliznyak, T., Johnson, F., de los Santos, C. (2012). Structure and stability of DNA containing an aristolactam II-dA lesion: implications for the NER recognition of bulky adducts. Nucleic Acids Res. 40 (6), 2759-2770. doi: 10.1093/nar/gkr1094
110. Luo, Q. (2013). Determination of aristolochic acid A in Ershiwuweishanhu Pill by HPLC. Drug Clinic 10 (14), 37-39. doi: 10.3969/j.issn.1672-2809.2013.14.010
111. Lv, Q. (2015). Limit test of aristolochic acid A in Zhuifengtougu Capsules. Chin. J. Modern Drug Appl. 9 (15), 285-286. doi: 10.14164/j.cnki.cn11-5581/r.2015.15.196
112. Lv, Y., Que, Y., Su, Q., Li, Q., Chen, X., Lu, H. (2016). Bioinformatics facilitating the use of microarrays to delineate potential miRNA biomarkers in aristolochic acid nephropathy. Oncotarget 7 (32), 52270-52280. doi: 10.18632/oncotarget.10586
113. Mao, W. W., Gao, W., Liang, Z. T., Li, P., Zhao, Z. Z., Li, H. J. (2017). Characterization and quantitation of aristolochic acid analogs in different parts of Aristolochiae Fructus, using UHPLCQ/TOF-MS and UHPLC-QQQ-MS. Chin. J. Nat. Med. 15 (5), 0392-0400. doi: 10.1016/S1875-5364(17)30060-2
114. Martinek, V., Barta, F., Hodek, P., Frei, E., Schmeiser, H. H., Arlt, V. M., et al. (2017). Comparison of the oxidation of carcinogenic aristolochic acid I and II by microsomal cytochromes P450 in vitro: experimental and theoretical approaches. Monatsh. Chem. 148 (11), 1971-1981. doi: 10.1007/s00706-017-2014-9
115. Martinek, V., Kubickova, B., Arlt, V. M., Frei, E., Schmeiser, H. H., Hudecek, J., et al. (2011). Comparison of activation of aristolochic acid I and II with NADPH:quinone oxidoreductase, sulphotransferases and N-acetyltranferases. Neuro. Endocrinol. Lett. 32 (Suppl 1), 57-70. doi: 10.3233/VES-2011-0426
116. Meinl, W., Pabel, U., Osterloh-Quiroz, M., Hengstler, J. G., Glatt, H. (2006). Human sulphotransferases are involved in the activation of aristolochic acids and are expressed in renal target tissue. Int. J. Cancer 118 (5), 1090-1097. doi: 10.1002/ijc.21480
117. Mengs, U. (1982). The carcinogenic action of aristolochic acid in rats. Arch. Toxicol. 51, 107-119. doi: 10.1007/BF00302751
118. Mengs, U. (1987). Acute toxicity of aristolochic acid in rodents. Arch. Toxicol. 59 (5), 328-331. doi: 10.1007/BF00295084
119. Mengs, U. (1988). Tumour induction in mice following exposure to aristolochic acid. Arch. Toxicol. 61 (6), 504-505. doi: 10.1007/BF00293699
120. Mengs, U., Stotzem, C. D. (1993). Renal toxicity of aristolochic acid in rats as an example of nephrotoxicity testing in routine toxicology. Arch. Toxicol. 67 (5), 307-311. doi: 10.1007/BF01973700
121. Meyer, M. M., Chen, T. P., Bennett, W. M. (2000). Chinese herb nephropathy. Proc. (Bayl Univ Med Cent). 13 (4), 334-337. doi: 10.1080/08998280.2000.11927699
122. Michl, J., Bello, O., Kite, G. C., Simmonds, M. S. J., Heinrich, M. (2017). Medicinally used Asarum species: high-resolution LC-MS analysis of aristolochic acid analogs and in vitro toxicity screening in HK-2 cells. Front. Pharmacol. 8, 215. doi: 10.3389/fphar.2017.00215
123. Michl, J., Ingrouille, M. J., Simmonds, M. S., Heinrich, M. (2014). Naturally occurring aristolochic acid analogues and their toxicities. Nat. Prod. Rep. 31 (5), 676-693. doi: 10.1039/c3np70114j
124. Michl, J., Jennings, H. M., Kite, G. C., Ingrouile, M. J., Simmonds, M. S., Heinrich, M. (2013). Is aristolochic acid nephropathy a widespread problem in developing countries? A case study of Aristolochia indica L. J. Ethnopharmacol. 149 (1), 235-244. doi: 10.1016/j.jep.2013.06.028
125. Michl, J., Kite, G. C., Wanke, S., Zierau, O., Vollmer, G., Neinhuis, C., et al. (2016). LC-MS- and 1H NMR-based metabolomic analysis and in vitro toxicological assessment of 43 Aristolochia species. J. Nat. Prod. 79 (1), 30-37. doi: 10.1021/acs.jnatprod.5b00556
126. Milichovsky, J., Barta, F., Schmeiser, H. H., Arlt, V. M., Frei, E., Stiborova, M., et al. (2016). Active site mutations as a suitable tool contributing to explain a mechanism of aristolochic acid I nitroreduction by cytochromes P450 1A1, 1A2 and 1B1. Int. J. Mol. Sci. 17 (2), 213. doi: 10.3390/ijms17020213
127. Miyazaki, J., Nishiyama, H. (2017). Epidemiology of urothelial carcinoma. Int. J. Urol. 24 (10), 730-734. doi: 10.1111/iju.13376
128. Mohamed, O. A., Wang, Z., Yu, G., Khalid, H. E. (1999). Determination of aristolochic acid A in the roots and rhizomes of Aristolochia from Sudan and China by HPLC. J. China Pharm. Univ. 30 (4), 288-290. doi: 10.1016/B978-008043005-8/50012-3
129. Moriya, M., Slade, N., Brdar, B., Medverec, Z., Tomic, K., Jelakovic, B., et al. (2011). TP53 mutational signature for aristolochic acid: an environmental carcinogen. Int. J. Cancer 129 (6), 1532-1536. doi: 10.1002/ijc.26077
130. Nault, J. C., Letouze, E. (2019). Mutational processes in hepatocellular carcinoma: the story of aristolochic acid. Semin. Liver Dis. doi: 10.1055/s-0039-1685516
131. Ng, A. W. T., Poon, S. L., Huang, M. N., Lim, J. Q., Boot, A., Yu, W., et al. (2017). Aristolochic acids and their derivatives are widely implicated in liver cancers in Taiwan and throughout Asia. Sci. Transl. Med. 9 (412). doi: 10.1126/scitranslmed.aan6446
132. Ni, L., Yang, X. (2012). Determination of hydroxysafflor yellow A, gallic acid, and aristolochic acid A in Wuweizhaxun Pill by HPLC. Chin. J. Exp. Tradit. Med. Formulae 18 (18), 109-112. doi: 10.13422/j.cnki.syfjx.2012.18.045
133. Nortier, J. L., Deschodt-Lanckman, M. M., Simon, S., Thielemans, N. O., de Prez, E. G., Depierreux, M. F., et al. (1997). Proximal tubular injury in Chinese herbs nephropathy: monitoring by neutral endopeptidase enzymuria. Kidney Int. 51 (1), 288-293. doi: 10.1038/ki.1997.35
134. Nortier, J. L., Martinez, M. C., Schmeiser, H. H., Arlt, V. M., Bieler, C. A., Petein, M., et al. (2000). Urothelial carcinoma associated with the use of a Chinese herb (Aristolochia fangchi). N. Engl. J. Med. 342 (23), 1686-1692. doi: 10.1056/NEJM200006083422301
135. Nortier, J. L., Vanherweghem, J. L. (2002). Renal interstitial fibrosis and urothelial carcinoma associated with the use of a Chinese herb (Aristolochia fangchi). Toxicology, 181-182, 577-580. doi: 10.1016/S0300-483X(02)00486-9
136. Pan, Y., Gan, Q. (2009). Determination of aristolochic acid A in prepared traditional Chinese medicines by LC-MS/MS. Phys. Test. Chem. Anal. (Part B: Chemical Analysis) 45 (9), 1017-1020. doi: 10.1360/972009-470
137. Pang, Y., Qu, J. (2015). Content determination of aristolochic acid A in Fufangquanshen Tablet. J. Pediatr. Pharm. 21 (11), 46-49. doi: 10.13407/j.cnki.jpp.1672-108X.2015.011.016
138. Patel, N., Arya, M., Muneer, A., Powles, T., Sullivan, M., Hines, J., et al. (2014). Molecular aspects of upper tract urothelial carcinoma. Urol. Oncol. 3228 (1), 28 e11-20. doi: 10.1016/j.urolonc.2012.10.002
139. Pavlovic, N. M. (2013a). Balkan endemic nephropathy-current status and future perspectives. Clin. Kidney J. 6 (3), 257-265. doi: 10.1093/ckj/sft049
140. Pavlovic, N. M., Maksimovic, V., Maksimovic, J. D., Orem, W. H., Tatu, C. A., Lerch, H. E., et al. (2013b). Possible health impacts of naturally occurring uptake of aristolochic acids by maize and cucumber roots: links to the etiology of endemic (Balkan) nephropathy. Environ. Geochem. Health 35 (2), 215-226. doi: 10.1007/s10653-012-9477-8
141. Poon, S. L., Huang, M. N., Choo, Y., McPherson, J. R., Yu, W., Heng, H. L., et al. (2015). Mutation signatures implicate aristolochic acid in bladder cancer development. Genome Med. 7 (1), 38. doi: 10.1186/s13073-015-0161-3
142. Poon, S. L., Pang, S. T., McPherson, J. R., Yu, W., Huang, K. K., Guan, P., et al. (2013). Genome-wide mutational signatures of aristolochic acid and its application as a screening tool. Sci. Transl. Med. 5 (197), 197ra101. doi: 10.1126/scitranslmed.3006086
143. Popovska-Jankovic, K., Noveski, P., Jankovic-Velickovic, L., Stojnev, S., Cukuranovic, R., Stefanovic, V., et al. (2016). MicroRNA profiling in patients with upper tract urothelial carcinoma associated with Balkan endemic nephropathy. Biomed. Res. Int. 2016, 7450461. doi: 10.1155/2016/7450461
144. Pozdzik, A. A., Berton, A., Schmeiset, H. H., Missoum, W., Decaestecker, C., Salmon, I. J., et al. (2010). Aristolochic acid nephropathy revisited: a place for innate and adaptive immunity? Histopathology 56 (4), 449-463. doi: 10.1111/j.1365-2559.2010.03509.x
145. Pu, X. Y., Shen, J. Y., Deng, Z. P., Zhang, Z. A. (2016). Oral exposure to aristolochic acid I induces gastric histological lesions with non-specific renal injury in rat. Exp. Toxicol. Pathol. 68 (6), 315-320. doi: 10.1016/j.etp.2016.03.003
146. Qiu, Q., Qin, C., Huang, Q. (2018). Determination of aristolochic acid A in Shennong snake liquor by HPLC. J. Guangxi Med. Univ. 35 (1), 116-118. doi: 10.16190/j.cnki.45-1211/r.2018.01.033
147. Ran, H., Tian, R., Huang, J. (2016). Determination of aristolochic acid I, oxypaeoniflorin, alibiflorin, and paeoniflorin in Yangyinjiangya Capsules by HPLC. Drugs Clinic 31 (11), 1703-1706. doi: 10.7501/j.issn.1674-5515.2016.11.004
148. Reginster, F., Jadoul, M., Van Ypersele de Strihou, C. (1997). Chinese herbs nephropathy presentation, natural history and fate after transplantation. Nephrol. Dial. Transplant. 12 (1), 81-86. doi: 10.1093/ndt/12.1.81
149. Ren, W., Li, S., Long, Y., Su, Z., Zhao, X. (2010). Limit detection of aristolochic acid A in Xinsheng Granula by HPLC. Tradit. Chin. Drug Res. Clin. Pharmacol. 21 (1), 67-69. doi: 10.19378/j.issn.1003-9783.2010.01.023
150. Rosenquist, T. A., Grollman, A. P. (2016). Mutational signature of aristolochic acid: clue to the recognition of a global disease. DNA Repair 44, 205-211. doi: 10.1016/j.dnarep.2016.05.027
151. Rosenquist, T. A., Einolf, H. J., Dickman, K. G., Wang, L., Smith, A., Grollman, A. P. (2010). Cytochrome P450 1A2 detoxicates aristolochic acid in the mouse. Drug Metab. Dispos. 38 (5), 761-768. doi: 10.1124/dmd.110.032201
152. Ruan, Y., Hu, X., Zhao, Y. (2012). Effect of Chinese herbal medicine compatibility on aristolochic acid content in Dangguisini Decoction. Chin. Arch. Tradit. Chin. Med. 30 (3), 549-551. doi: 10.13193/j.archtcm.2012.03.103.ruanyp.049
153. Rui, H. L., Wang, Y. Y., Cheng, H., Chen, Y. P. (2012). JNK-dependent AP-1 activation is required for aristolochic acid-induced TGF-beta1 synthesis in human renal proximal epithelial cells. Am. J. Physiol. Renal Physiol. 302 (12), F1569-1575. doi: 10.1152/ajprenal.00560.2011
154. Sato, N., Takahashi, D., Chen, S. M., Tsuchiya, R., Mukoyama, T., Yamagata, S., et al. (2004). Acute nephrotoxicity of aristolochic acids in mice. J. Pharm. Pharmacol. 56 (2), 221-229. doi: 10.1211/0022357023051
155. Scelo, G., Riazalhosseini, Y., Greger, L., Letouneau, L., Gonzalea-Porta, M., Wozniak, M. B., et al. (2014). Variation in genomic landscape of clear cell renal cell carcinoma across Europe. Nat. Commun. 5, 5135. doi: 10.1038/ncomms6135
156. Schaneberg, B. T., Khan, I. A. (2004). Analysis of products suspected of containing Aristolochia or Asarum species. J. Ethnopharmacol. 94 (2-3), 245-249. doi: 10.1016/j.jep.2004.06.010
157. Schmeiser, H. H., Bieler, C. A., Wiessler, M., van Ypersele de Strihou, C., Cosyns, J. P. (1996). Detection of DNA adducts formed by aristolochic acid in renal tissue from patients with Chinese herbs nephropathy. Cancer Res. 56 (9), 2025-2028. doi: 10.1007/s002620050279
158. Schmeiser, H. H., Frei, E., Wiessler, M., Stiborova, M. (1997). Comparison of DNA adduct formation by aristolochic acids in various in vitro activation systems by 32P-post-labelling: evidence for reductive activation by peroxidases. Carcinogenesis 18 (5), 1055-1062. doi: 10.1093/carcin/18.5.1055
159. Schmeiser, H. H., Janssen, J. W., Lyons, J., Scherf, H. R., Pfau, W., Buchmann, A., et al. (1990). Aristolochic acid activates ras genes in rat tumors at deoxyadenosine residues. Cancer Res. 50 (17), 5464-5469. doi: 10.1016/0304-3835(90)90217-L
160. Schmeiser, H. H., Kucab, J. E., Arlt, V. M., Phillips, D. H., Hollstein, M., Gluhovschi, G., et al. (2012). Evidence of exposure to aristolochic acid in patients with urothelial cancer from a Balkan endemic nephropathy region of Romania. Environ. Mol. Mutagen. 53 (8), 636-641. doi: 10.1002/em.21732
161. Schmeiser, H. H., Nortier, J. L., Singh, R., Gamboa da Costa, G., Sennesael, J., Cassuto-Viguier, E., et al. (2014). Exceptionally long-term persistence of DNA adducts formed by carcinogenic aristolochic acid I in renal tissue from patients with aristolochic acid nephropathy. Int. J. Cancer 135 (2), 502-507. doi: 10.1002/ijc.28681
162. Shaohua, Z., Ananda, S., Ruxia, Y., Liang, R., Xiaorui, C., Liang, L. (2010). Fatal renal failure due to the Chinese herb “GuanMuTong” (Aristolochia manshuriensis): autopsy findings and review of literature. Forensic Sci. Int. 199 (1-3), e5-7. doi: 10.1016/j.forsciint.2010.02.003
163. Shen, M., Xu, G., Zhang, Q. (2008). Determination of the contents of aristolochic acid A in Longdanxiegan Pills by high performance liquid chromatography. Her. Med. 27 (2), 221-222. doi: 10.3870/j.issn.1004-0781.2008.02.043
164. Shibutani, S., Dong, H., Suzuki, N., Ueda, S., Miller, F., Grollman, A. P. (2007). Selective toxicity of aristolochic acids I and II. Drug Metab. Dispos. 35 (7), 1217-1222. doi: 10.1124/dmd.107.014688
165. Shu, X., Chen, J., Lin, S., Yu, N., Ye, X., Xie, D., et al. (2016). Determination of limit of aritolochic acid A in Dahuangqingwei Pills. Chin. J. Hosp. Pharmacy 36 (17), 1512-1515. doi: 10.13286/j.cnki.chinhosppharmacyj.2016.17.19
166. Sidorenko, V. S., Attaluri, S., Zaitseva, I., Iden, C. R., Dickman, K. G., Johnson, F., et al. (2014). Bioactivation of the human carcinogen aristolochic acid. Carcinogenesis 35 (8), 1814-1822. doi: 10.1093/carcin/bgu095
167. Sidorenko, V. S., Yeo, J. E., Bonala, R. R., Johnson, F., Scharer, O. D., Grollman, A. P. (2012). Lack of recognition by global-genome nucleotide excision repair accounts for the high mutagenicity and persistence of aristolactam-DNA adducts. Nucleic Acids Res. 40 (6), 2494-2505. doi: 10.1093/nar/gkr1095
168. Slade, N., Moll, U. M., Brdar, B., Zoric, A., Jelakovic, B. (2009). P53 mutations as fingerprints for aristolochic acid: an environmental carcinogen in endemic (Balkan) nephropathy. Mutat. Res. 663 (1-2), 1-6. doi: 10.1016/j.mrfmmm.2009.01.005
169. Soria, F., Shariat, S. F., Lerner, S. P., Fritsche, H. M., Rink, M., Kassouf, W., et al. (2017). Epidemiology, diagnosis, preoperative evaluation and prognostic assessment of upper-tract urothelial carcinoma (UTUC). World J. Urol. 35 (3), 379-387. doi: 10.1007/s00345-016-1928-x
170. Stefanovic, V., Jelakovic, B., Cukuranovic, R., Bukvic, D., Nikolic, J., Lukic, L., et al. (2007). Diagnostic criteria for Balkan endemic nephropathy: proposal by an international panel. Ren. Fail. 29 (7), 867-880. doi: 10.1080/08860220701600732
171. Stefanovic, V., Toncheva, D., Atanasova, S., Polenakovic, M. (2006). Etiology of Balkan endemic nephropathy and associated urothelial cancer. Am. J. Nephrol. 26 (1), 1-11. doi: 10.1159/000090705
172. Stiborova, M., Arlt, V. M., Schmeiser, H. H. (2016). Balkan endemic nephropathy: an update on its aetiology. Arch. Toxicol. 90 (11), 2595-2615. doi: 10.1007/s00204-016-1819-3
173. Stiborova, M., Arlt, V. M., Schmeiser, H. H. (2017). DNA adducts formed by aristolochic acid are unique biomarkers of exposure and explain the initiation phase of upper urothelial cancer. Int. J. Mol. Sci. 18 (10). doi: 10.3390/ijms18102144
174. Stiborova, M., Barta, F., Levova, K., Hodek, P., Schmeiser, H. H., Arlt, V. M., et al. (2015). A mechanism of O-demethylation of aristolochic acid I by cytochromes P450 and their contributions to this reaction in human and rat livers: experimental and theoretical approaches. Int. J. Mol. Sci. 16 (11), 27561-27575. doi: 10.3390/ijms161126047
175. Stiborova, M., Frei, E., Arlt, V. M., Schmeiser, H. H. (2008a). Metabolic activation of carcinogenic aristolochic acid, a risk factor for Balkan endemic nephropathy. Mutat. Res. 658 (1-2), 55-67. doi: 10.1016/j.mrrev.2007.07.003
176. Stiborova, M., Frei, E., Arlt, V. M., Schmeiser, H. H. (2009). The role of biotransformation enzymes in the development of renal injury and urothelial cancer caused by aristolochic acid: urgent questions and difficult answers. Biomed. Pap. Med. Fac. Univ. Palacky Olomouc Czech. Repub. 153 (1), 5-11. doi: 10.5507/bp.2009.001
177. Stiborova, M., Frei, E., Hodek, P., Wiessler, M., Schmeiser, H. H. (2005). Human hepatic and renal microsomes, cytochromes P450 1A1/2, NADPH:cytochrome P450 reductase and prostaglandin H synthase mediate the formation of aristolochic acid-DNA adducts found in patients with urothelial cancer. Int. J. Cancer 113 (2), 189-197. doi: 10.1002/ijc.20564
178. Stiborova, M., Frei, E., Schmeiser, H. H. (2008b). Biotransformation enzymes in development of renal injury and urothelial cancer caused by aristolochic acid. Kidney Int. 73 (11), 1209-1211. doi: 10.1038/ki.2008.125
179. Stiborova, M., Hudecek, J., Frei, E., Schmeiser, H. H. (2008c). Contribution of biotransformation enzymes to the development of renal injury and urothelial cancer caused by aristolochic acid: urgent questions, difficult answers. Interdiscip. Toxicol. 1 (1), 8-12. doi: 10.2478/v10102-010-0023-1
180. Stiborova, M., Levova, K., Barta, F., Shi, Z., Frei, E., Schmeiser, H. H., et al. (2012). Bioactivation versus detoxication of the urothelial carcinogen aristolochic acid I by human cytochrome P450 1A1 and 1A2. Toxicol. Sci. 125 (2), 345-358. doi: 10.1093/toxsci/kfr306
181. Stiborova, M., Mares, J., Frei, E., Arlt, V. M., Martinek, V., Schmeiser, H. H., et al. (2011). The human carcinogen aristolochic acid I is activated to form DNA adducts by human NAD(P)H:quinone oxidoreductase without the contribution of acetyltransferases or sulfotransferases. Environ. Mol. Mutagen. 52 (6), 448-459. doi: 10.1002/em.20642
182. Sun, M., Zhang, J., Zheng, C., Liu, Y., Lin, F., Xu, F., et al. (2015). Analysis of potential risk factors for cancer incidence in patients with aristolochic acid nephropathy from Wenzhou, China. Ren. Fail. 37 (2), 209-213. doi: 10.3109/0886022X.2014.990347
183. Tan, R., Shi, X., Yang, J. (2005). Determination of aristolochic acid in Ershiwuwei songshi Capsule by HPLC. J. Chin. Med. Mater. 28 (7), 619-620. doi: 10.13863/j.issn1001-4454.2005.07.042
184. Tang, X., He, S., Xie, T. (2012). Determination of aristolochic acid A in Xiaozhongzhitong Tincture by SPE-HPLC. Chin. J. Pharm. Anal. 32 (9), 1690-1693. doi: 10.16155/j.0254-1793.2012.09.025
185. Tao, L., Zeng, Y., Wang, J., Liu, Z., Shen, B., Ge, J., et al. (2015). Differential microRNA expression in aristolochic acid-induced upper urothelial tract cancers ex vivo. Mol. Med. Rep. 12 (5), 6533-6546. doi: 10.3892/mmr.2015.4330
186. Tian, H., Wang, H. (2007). Determination of aristolochic acid A in Wantongjingu Tablet by RP-HPLC. Pharm. J. Chin. People's Liberation Army 23 (6), 456-457. doi: 10.3969/j.issn.1008-9926.2007.06.021
187. Toncheva, D., Mihailova-Hristova, M., Vazharova, R., Staneva, R., Karachanak, S., Dimitrov, P., et al. (2014). NGS nominated CELA1, HSPG2, and KCNK5 as candidate genes for predisposition to Balkan endemic nephropathy. Biomed. Res. Int. 2014, 920723. doi: 10.1155/2014/920723
188. Totoki, Y., Tatsuno, K., Covington, K. R., Ueda, H., Creighton, C. J., Kato, M., et al. (2014). Transancestry mutational landscape of hepatocellular carcinoma genomes. Nat. Genet. 46 (12), 1267-1273. doi: 10.1038/ng.3126
189. Trnacevic, S., Nislic, E., Trnacevic, E., Tulumovic, E. (2017). Early screening of Balkan endemic nephropathy. Mater. Sociomed. 29 (3), 207-210. doi: 10.5455/msm.2017.29.207-210
190. Vaclavik, Krynitsky, A. J., Rader, J. I. (2014). Quantification of aristolochic acids I and II in herbal dietary supplements by ultra-high-performance liquid chromatography-multistage fragmentation mass spectrometry. Food Addit. Contam. Part A Chem. Anal. Control Expo. Risk Assess. 31 (5), 784-791. doi: 10.1080/19440049.2014.892215
191. Vanhaelen, M., Vanhaelen-Fastre, R., But, P., Vanherveghem, J. L. (1994). Identification of aristolochic acid in Chinese herbs. Lancet 343 (8890), 174.
192. Vanherweghem, J., Depierreux, M., Tielemans, C., Abramowicz, D., Dratwa, M., Jadoul, M., et al. (1993). Rapidly progressive interstitial renal fibrosis in young women: association with slimming regimen including Chinese herbs. Lancet 341 (8842), 387-391. doi: 10.1016/0140-6736(93)92984-2
193. Veale, E. L., Mathie, A. (2016). Aristolochic acid, a plant extract used in the treatment of pain and linked to Balkan endemic nephropathy, is a regulator of K2P channels. Br. J. Pharmacol. 173 (10), 1639-1652. doi: 10.1111/bph.13465
194. Vervaet, B. A., D'Haese, P. C., Verhulst, A. (2017). Environmental toxin-induced acute kidney injury. Clin. Kidney J. 10 (6), 747-758. doi: 10.1093/ckj/sfx062
195. Wang, Y., Chan, W. (2014). Determination of aristolochic acids by high-performance liquid chromatography with fluorescence detection. J. Agric. Food Chem. 62 (25), 5859-5864. doi: 10.1021/jf501609j
196. Wang, C., Juan, H., Li, H. (2017). HPLC determination of aristolochic acid in Yishenjuanbi Pill. Journal of Harbin University of Commerce (Natural Sciences Edition). 33 (4), 406-410. doi: 10.19492/j.cnki.1672-0946.2017.04.006
197. Wang, H., Yang, S., Bai, S. (2018a). Progress on chemical constituents and bioactivities of Saruma Henryi Oliv. Food Drug 20 (2), 157-160. doi: 10.3969/j.issn.1672-979X.2018.02.020
198. Wang, L., Ding, X., Li, C., Zhao, Y., Yu, C., Yi, Y., et al. (2018b). Oral administration of Aristolochia manshuriensis Kom in rats induces tumors in multiple organs. J. Ethnopharmacol. 225, 81-89. doi: 10.1016/j.jep.2018.07.001
199. Wang, S. M., Lai, M. N., Chen, P. C., Pu, Y. S., Lai, M. K., Hwang, J. S., et al. (2014a). Increased upper and lower tract urothelial carcinoma in patients with end-stage renal disease: a nationwide cohort study in Taiwan during 1997-2008. Biomed. Res. Int. 2014, 149750. doi: 10.1155/2014/149750
200. Wang, S. M., Lai, M. N., Wei, A., Chen, Y. Y., Pu, Y. S., Chen, P. C., et al. (2014b). Increased risk of urinary tract cancer in ESRD patients associated with usage of Chinese herbal products suspected of containing aristolochic acid. PLoS One 9 (8), e105218. doi: 10.1371/journal.pone.0105218
201. Wang, Y., Meng, F., Arlt, V. M., Mei, N., Chen, T., Parsons, B. L. (2011). Aristolochic acid-induced carcinogenesis examined by ACB-PCR quantification of H-Ras and K-Ras mutant fraction. Mutagenesis 26 (5), 619-628. doi: 10.1093/mutage/ger023
202. Wei, F., Cheng, X. L., Ma, L. Y., Jin, W. T., Schaneberg, B. T., Khan, I. A., et al. (2005). Analysis of aristolochic acids and analogues in medicinal plants and their commercial products by HPLC-PAD-ESI/MS. Phytochem. Anal. 16 (3), 222-230. doi: 10.1002/pca.849
203. Wei, J., Mo, Y., Liang, S. (2007). Limit detection of aristolochic acid in Ganteling Capsules. Chin. Traditional Patent Med. 29 (8), 1266-1267. doi: 10.3969/j.issn.1001-1528.2007.08.061
204. Wei, Y., Wang, H., Liu, Y., Liu, H., Han, X., Song, X. (2011). Determination of the contents of aristolochic acid A in Aristolochia moupinensis and Qiweihonghuashusheng Pills. Chin. Traditional Patent Med. 33 (12), 2186-2188. doi: 10.1038/cdd.2010.68
205. Wen, H., Gao, H. Y., Qi, W., Xiao, F., Wang, L. L., Wang, D., et al. (2014). Simultaneous determination of twenty-two components in Asari Radix et Rhizoma by ultra performance liquid chromatography coupled with quadrupole time-of-flight mass spectrometry. Planta Med. 80 (18), 1753-1762. doi: 10.1055/s-0034-1383296
206. Wooltorton, E. (2004). Several Chinese herbal products may contain toxic aristolochic acid. CMAJ 171 (5), 449. doi: 10.1503/cmaj.1041266
207. Wu, F. L., Chen, Y. M., Lai, T. S., Shen, L. J., Ho, Y. F., Lee, Y. T., et al. (2012). Does Chinese herb nephropathy account for the high incidence of end-stage renal disease in Taiwan? Nephron. Clin. Pract. 120 (4), c215-222. doi: 10.1159/000341120
208. Wu, J., Wu, C., Qiao, M. (2009). Detection on contents of aristolochic acid A in Daochi Powder and its combination group with high performance liquid chromatography. J. Hubei Univ. Chin. Med. 11 (3), 30-31. doi: 10.3969/j.issn.1008-987X.2009.03.012
209. Wu, X. (2006). Determination of aristolochine A in Guanxinsuhe Pills by RP-HPLC. J. Zhejiang Chin. Med. Univ. 30 (5), 535-536. doi: 10.3969/j.issn.1005-5509.2006.05.048
210. Xiao, Y., Ge, M., Xue, X., Wang, C., Wang, H., Wu, X., et al. (2008). Hepatic cytochrome P450s metabolize aristolochic acid and reduce its kidney toxicity. Kidney Int. 73 (11), 1231-1239. doi: 10.1038/ki.2008.103
211. Xing, G., Qi, X., Chen, M., Wu, Y., Yao, J., Gong, L., et al. (2012). Comparison of the mutagenicity of aristolochic acid I and aristolochic acid II in the gpt delta transgenic mouse kidney. Mutat. Res. 743 (1-2), 52-58. doi: 10.1016/j.mrgentox.2011.12.021
212. Xu, Y., Shang, M., Ge, Y., Wang, X., Cai, S. (2010). Chemical constituent from fruit of Aristolochia contorta.. China J. Chin. Mater. Med. 35 (21), 2862-2865. doi: 10.4268/cjcmm20102115
213. Xu, Y. Q., Li, X. W., Liu, G. X., Wang, X., Shang, M. Y., Li, X. M., et al. (2013). Comparative study of the contents of analogues of aristolochic acid in two kinds of Aristolochiae Fructus by high-performance liquid chromatography. J. Nat. Med. 67 (1), 113-122. doi: 10.1007/s11418-012-0664-9
214. Xue, L. (2015). Determination of the content of aristolochic acid in Rumozhentong Capsule. Shanxi J. Traditional Chin. Med. 36 (4), 492-493. doi: 10.3969/j.issn.1000-7369.2015.04.049
215. Xue, X., Gong, L. K., Maeda, K., Luan, Y., Qi, X. M., Sugiyama, Y., et al. (2011). Critical role of organic anion transporters 1 and 3 in kidney accumulation and toxicity of aristolochic acid I. Mol. Pharm. 8 (6), 2183-2192. doi: 10.1021/mp100418u
216. Yang, H. Y., Chen, P. C., Wang, J. D. (2014). Chinese herbs containing aristolochic acid associated with renal failure and urothelial carcinoma: a review from epidemiologic observations to causal inference. Biomed. Res. Int. 2014, 569325. doi: 10.1155/2014/569325
217. Yang, H. Y., Lin, J. L., Chen, K. H., Yu, C. C., Hsu, P. Y., Lin, C. L. (2006). Aristolochic acid-related nephropathy associated with the popular Chinese herb Xixin. J. Nephrol. 19 (1), 111-114. doi: 10.1016/S0269-7491(99)00120-7
218. Yang, L., Su, T., Li, X. M., Wang, X., Cai, S. Q., Meng, L. Q., et al. (2012). Aristolochic acid nephropathy: variation in presentation and prognosis. Nephrol. Dial. Transplant. 27 (1), 292-298. doi: 10.1093/ndt/gfr291
219. Ye, Z., Zhang, Y., Wang, Y. (2003). Determination of aristolonchic acid A content in Caulis Aristolochiae Manshuriensis and other four aristolonchic Chinese herb drugs by HPLC. Fudan Univ. J. Med. Sci. 30 (5), 491-493. doi: 10.3969/j.issn.1672-8467.2003.05.022
220. Yi, J. H., Han, S. W., Kim, W. Y., Kim, J., Park, M. H. (2018). Effects of aristolochic acid I and/or hypokalemia on tubular damage in C57BL/6 rat with aristolochic acid nephropathy. Korean J. Intern. Med. 33 (4), 763-773. doi: 10.3904/kjim.2016.097
221. Yin, S., Wang, M., Lin, X., Li, J., Xie, H. (2009). Determination of aristolochic acid A in Fufangnanxingzhitong Ointment by UPLC. J. Nanjing Univ. Tradit. Chinese Med. 25 (5), 396-397. doi: 10.3969/j.issn.1000-5005.2009.05.025
222. Yu, B., Liu, Z., Li, S. (2011a). Limit detection of aristolochic acid I in Gubenqufeng Granules. China Pharmacy 22 (47), 4485-4486.
223. Yu, F., Wu, T. S., Chen, T. W., Liu, B. H. (2011b). Aristolochic acid I induced oxidative DNA damage associated with glutathione depletion and ERK1/2 activation in human cells. Toxicol. Vitro 25 (4), 810-816. doi: 10.1016/j.tiv.2011.01.016
224. Yu, J., Ma, C. M., Wang, X., Shang, M. Y., Hattori, M., Xu, F., et al. (2016). Analysis of aristolochic acids, aristololactams and their analogues using liquid chromatography tandem mass spectrometry. Chin. J. Nat. Med. 14 (8), 0626-0640. doi: 10.1016/S1875-5364(16)30074-7
225. Yuan, J., Liu, Q., Wei, G., Tang, F., Ding, L., Yao, S. (2007a). Characterization and determination of six aristolochic acids and three aristololactams in medicinal plants and their preparations by high-performance liquid chromatography-photodiode array detection/electrospray ionization mass spectrometry. Rapid Commun. Mass Spectrom. 21 (14), 2332-2342. doi: 10.1002/rcm.3097
226. Yuan, J., Liu, Q., Zhu, W., Ding, L., Tang, F., Yao, S. (2008). Simultaneous analysis of six aristolochic acids and five aristolactams in herbal plants and their preparations by high-performance liquid chromatography-diode array detection-fluorescence detection. J. Chromatogr. A 1182 (1), 85-92. doi: 10.1016/j.chroma.2007.12.076
227. Yuan, J., Nie, L., Zeng, D., Luo, X., Tang, F., Ding, L. (2007b). Simultaneous determination of nine aristolochic acid analogues in medicinal plants and preparations by high-performance liquid chromatography. Talanta 73 (4), 644-650. doi: 10.1016/j.talanta.2007.04.042
228. Yuan, J., Zhang, X. (2016). Simultaneous determination of contents of five components in Guanxinsuhe dripping Pills by HPLC with gradient elution method. Anhui Med. Pharm. J. 20 (9), 1651-1654. doi: 10.3969/j.issn.1009-6469.2016.09.010
229. Zhai, Z., Luo, X., Shi, Y. (2006). Separation and determination of aristolochic acids in herbal medicines by microemulsion electrokinetic chromatography. Anal. Chim. Acta 561 (1-2), 119-125. doi: 10.1016/j.aca.2006.01.025
230. Zhang, C., Wang, X., Shang, M., Yu, J., Xu, Y., Li, Z., et al. (2006). Simultaneous determination of five aristolochic acids and two aristololactams in Aristolochia plants by high-performance liquid chromatography. Biomed. Chromatogr. 20 (4), 309-318. doi: 10.1002/bmc.565
231. Zhang, H., Li, J., Sun, X. (2013a). Determination of aristolochic acid I in Ershijiuweinengxiao Powder by HPLC. Chin. Pharm. Affairs 27 (12), 1269-1271.
232. Zhang, H. M., Zhao, X. H., Sun, Z. H., Li, G. C., Liu, G. C., Sun, L. R., et al. (2019). Recognition of the toxicity of aristolochic acid. J. Clin. Pharm. Ther. 44 (2), 157-162. doi: 10.1111/jcpt.12789
233. Zhang, H. (2017). Limited determination of aristolochic acid I in Biyanling Tablet. Chin. J. Ration. Drug Use 14 (7), 67-69. doi: 10.3969/j.issn.2096-3327.2017.07.020
234. Zhang, J., Wei, Z., Zhang, A., Zhao, Y., Zhao, G., Cai, X., et al. (2016). Detection aristolochic acids 1 and 2 in Costustoot via electrochemical method and liquid chromatography. Int. J. Electrochem. Sci. 11 (8), 6830-6837. doi: 10.20964/2016.08.11
235. Zhang, L., Wang, Y. (2012). LC-MS detection of aristolochic acid A in Xiaofengzhiyang Granula. Chin. J. Pharm. Anal. 32 (1), 78-81. doi: 10.16155/j.0254-1793.2012.01.006
236. Zhang, P. (2011). The assay of aristolochic acid A in different organs of Saruma.. North. Hortic. (20), 177-178.
237. Zhang, P., Wei, J., Zhang, F., Gu, J. (2013b). Extraction and determination of four different aristolochic acids in aristolochic herbs and Chinese patent drug. Mod. Tradit. Chin. Med. Mater. Med. World Sci. Technol. 15 (1), 6. doi: 10.3969/j.issn.1674-3849.2013.01.025
238. Zhao, H., Jiang, H. (2009). Determination of aristolochic acid A in Saruma henryi by HPLC. Guihaia 29 (4), 548-551. doi: 10.3969/j.issn.1000-3142.2009.04.027
239. Zhao, Y. Y., Wang, H. L., Cheng, X. L., Wei, F., Bai, X., Lin, R. C., et al. (2015). Metabolomics analysis reveals the association between lipid abnormalities and oxidative stress, inflammation, fibrosis, and Nrf2 dysfunction in aristolochic acid-induced nephropathy. Sci. Rep. 5, 12936. doi: 10.1038/srep12936
240. Zhou, Q., Pei, J., Poon, J., Lau, A. Y., Zhang, L., Wang, Y., et al. (2019). Worldwide research trends on aristolochic acids (1957-2017): suggestions for researchers. PLoS One 14 (5), e0216135. doi: 10.1371/journal.pone.0216135
241. Zhou, X., Li, Z., Chen, Y., Li, P. (2015). Determination the limitation of aristolochic acid A in Mahuangzhisou Pill by SPE-HPLC. Guiding J. Tradit. Chin. Med. Pharmacy 21 (14), 44-46. doi: 10.13862/j.cnki.cn43-1446/r.2015.14.014
242. Zhou, Y., Zhou, J., Huang, S., Wu, P., Wang, Y., Du, X., et al. (2008). RP-HPLC determination of aristolochic acid A in some Aristolochiaceae Chinese herbal medicine. Chin. J. Pharm. Anal. 28 (7), 1075-1080. doi: 10.1016/S1872-2040(08)60074-2
243. Zhu, G., Wang, Q., Wang, Z., Su, X. (2006). Determination of the content of aristolochic acid I and II in Ganluxiaodu Pills with RP-HPLC. Her. Med. 25 (6), 568-570. doi: 10.3870/j.issn.1004-0781.2006.06.035